España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Eisai Co
ESAIY
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$6.80
0.04
0.59%
At close: -
Get Report
Comment
Eisai Co (ESAIY) Forecast
News
Earnings
Eisai Co (ESAIY) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Eisai Co (OTC:ESAIY) Stock
Eisai Co Stock (OTC: ESAIY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, November 29, 2024
Reported Wednesday, Eisai and Biogen Introduc...
Benzinga Newsdesk
Thursday, November 14, 2024
CHMP Recommends EU Approval For Eisai's Leqem...
Benzinga Newsdesk
Thursday, August 22, 2024
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
Vandana Singh
Wednesday, July 03, 2024
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
Vandana Singh
Tuesday, June 11, 2024
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Nabaparna Bhattacharya
Monday, June 10, 2024
Eisai And Biogen Announced FDA Accepts Filing...
Benzinga Newsdesk
Wednesday, May 15, 2024
Reported Earlier, Biogen And Eisai Initiated ...
Benzinga Newsdesk
Monday, April 01, 2024
Reported Earlier, Eisai Completed Submission ...
Benzinga Newsdesk
Tuesday, November 21, 2023
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Vandana Singh
Monday, September 25, 2023
Biogen And Eisai's LEQEMBI Intravenous Infusi...
Benzinga Newsdesk
Friday, August 25, 2023
Merck, Eisai Provide Update On Phase 3 LEAP-0...
Benzinga Newsdesk
Friday, July 07, 2023
Stocks Rebound, Dollar Tumbles As June Jobs Data Eases Fed Hike Wagers: What's Driving Markets Friday?
Shanthi Rexaline
Thursday, July 06, 2023
FDA Converts Novel Alzheimer's Disease Treatment To Traditional Approval; Action Follows Confirmatory Trial To Verify Clinical Benefit
Happy Mohamed
Wednesday, March 22, 2023
iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach
Rachael Green
-
Sponsored
Monday, March 06, 2023
FDA Accepted Eisai-Biogen's Supplemental Biol...
Benzinga Newsdesk
Tuesday, February 28, 2023
Reported Late Monday Feb. 27, Eisai Co. And Biogen Inc. Announce Biologics License Application For Lecanemab Designated For Priority Review By China National Medical Products Administration
Happy Mohamed
Friday, February 17, 2023
'Maker Of Promising Alzheimer's Drug Leqembi Expects Full FDA Approval This Summer, Expanded Medicare Coverage' - CNBC
Happy Mohamed
